Results 1 to 10 of about 47,347 (213)

Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome [PDF]

Scientific Reports, 2017
The dopamine partial agonist aripiprazole is increasingly used to treat pathologies for which other antipsychotics are indicated because it displays fewer side effects, such as sedation and depression-like symptoms, than other dopamine receptor ...
Alexandre Salvador, Yulia Worbe, Cécile Delorme, Giorgio Coricelli, Raphaël Gaillard, Trevor W. Robbins, Andreas Hartmann, Stefano Palminteri   +7 more
doaj   +4 more sources

We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database

Frontiers in Psychiatry, 2020
Background: Although aripiprazole and risperidone are used widespread in pediatrics, there are still limited pieces of evidence on their actual safety profile.
Concetta Rafaniello, Maria Giuseppa Sullo, Carla Carnovale, Marco Pozzi, Barbara Stelitano, Sonia Radice, Renato Bernardini, Francesco Rossi, Emilio Clementi, Emilio Clementi, Annalisa Capuano   +10 more
doaj   +2 more sources

Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports [PDF]

Mental Health Clinician, 2021
Aripiprazole, an atypical antipsychotic, is a metabolic substrate for cytochrome P450 (CYP)3A4 and 2D6. Terbinafine, an antifungal agent used for onychomycosis, is a CYP2D6 inhibitor and could theoretically reduce the metabolism of aripiprazole. However,
Ian R. McGrane, PharmD, Tori J. Lindbloom, PharmD candidate, Robert C. Munjal, MD   +2 more
doaj   +1 more source

Memantine/Aripiprazole Combination Alleviates Cognitive Dysfunction in Valproic Acid Rat Model of Autism: Hippocampal CREB/BDNF Signaling and Glutamate Homeostasis

Neurotherapeutics, 2023
Significant efforts are increasingly directed towards identifying novel therapeutic targets for autism spectrum disorder (ASD) with a rising role of aberrant glutamatergic transmission in the pathogenesis of ASD-associated cellular and behavioral ...
Sohir M. Zohny, Mohamed Z. Habib, Magda I. Mohamad, W. Elayat, R. Elhossiny, Mohamed F Abd El-Salam, G. Hassan, Sawsan Aboul-Fotouh   +7 more
semanticscholar   +1 more source

A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder

CNS Drugs, 2023
Aripiprazole is a medication used to treat psychotic symptoms in schizophrenia or bipolar I disorder (BP-I) that can be taken orally or injected into the muscle.
M. Harlin, Murat Yildirim, P. Such, J. Madera-McDonough, Michael Jan, N. Jin, S. Watkin, F. Larsen   +7 more
semanticscholar   +1 more source

Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis

Psychopharmacology, 2022
While one of the basic axioms of pharmacology postulates that there is a relationship between the concentration and effects of a drug, the value of measuring blood levels is questioned by many clinicians.
X. Hart, C. Hiemke, L. Eichentopf, X. Lense, H. Clement, A. Conca, F. Faltraco, V. Florio, Jessica Grüner, U. Havemann-Reinecke, E. Molden, M. Paulzen, G. Schoretsanitis, T. Riemer, G. Gründer   +14 more
semanticscholar   +1 more source

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia

BMC Psychiatry, 2023
Background Distinct oral atypical antipsychotics have different effects on autonomic nervous system (ANS) activity. Among them, oral aripiprazole has been linked to dysfunction of the ANS in schizophrenia.
Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimoto   +16 more
doaj   +1 more source

Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats

InflammoPharmacology, 2022
Schizophrenia is a common mental disorder affecting patients’ thoughts, behavior, and cognition. Recently, the NRG1/ErbB4 signaling pathway emerged as a candidate therapeutic target for schizophrenia.
Dalia A. Nawwar, Hala F Zaki, R. H. Sayed   +2 more
semanticscholar   +1 more source

The Effectiveness and Adverse Events of Amitriptyline and Aripiprazole in Very Elderly Patients With BMS

Frontiers in Pain Research, 2022
Burning mouth syndrome (BMS) is defined by chronic oral burning sensations without any corresponding abnormalities. Besides amitriptyline, aripiprazole has been reported as a possible medication to manage BMS.
M. Watanabe, C. Takao, Zhenyang Liu, Gayatri Nayanar, T. Suga, Chaoli Hong, T. Tu, Tatsuya Yoshikawa, Miho Takenoshita, Haruhiko Motomura, T. Nagamine, A. Toyofuku   +11 more
semanticscholar   +1 more source

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone

Frontiers in Pharmacology, 2021
Olanzapine, aripiprazole and risperidone are atypical antipsychotics or neuroleptics widely used for schizophrenia treatment. They induce various adverse drug reactions depending on their mechanisms of action: metabolic effects, such as weight gain and ...
Paula Soria-Chacartegui, Gonzalo Villapalos-García, P. Zubiaur, F. Abad‐Santos, D. Koller   +4 more
semanticscholar   +1 more source